Oncotarget

Cancer treatment is moving toward a more precision-based approach, where therapies are guided not just by the tumor’s location but also by its genetic features. Mutations in cancer cells can point to specific drugs that may be more effective for certain patients. However, detecting these mutations often requires broad and detailed analysis. This is where comprehensive genomic profiling becomes especially important. One of the main challenges in cancer care is that many existing genetic tools focus on only a limited number of mutations. As a result, some treatment opportunities may be missed. Certain mutations are also difficult to detect because they occur at low levels or exist in complex forms, such as gene fusions. Without advanced screening methods, these changes may go unnoticed. To address these challenges, researchers from Exact Sciences Corporation conducted a large-scale study using a broad genomic screening approach. The findings were recently published in the journal Oncotarget. Full blog - https://www.oncotarget.org/2025/12/15/comprehensive-genomic-profiling-in-cancer-insights-from-over-10000-tumors/ Paper DOI - https://doi.org/10.18632/oncotarget.28757 Correspondence to - Jean-Paul De La O - jdelao@exactsciences.com Abstract video - https://www.youtube.com/watch?v=awiRhDfiMTE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28757 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, solid tumors, comprehensive genomic profiling, matched therapy, gene fusions, limit of detection To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Colorectal cancer is a leading cause of cancer deaths, prompting researchers to explore repurposing existing drugs like statins for treatment. Discover how statins may suppress the Wnt/β-catenin signaling pathway, a key driver of tumor growth. The study reveals that statins downregulate the SATB1 protein while increasing SATB2, influencing cancer cell behavior. Additionally, statins showed promise in disrupting tumor structure and reducing growth in lab models. Tune in for insights on the potential clinical implications and future research directions!

Cancer's sneaky Tregs protect tumors by suppressing immune responses. Traditional treatments struggle against these cells due to their interference with vital IL-2 levels. However, researchers have unveiled a game-changing antibody, 2B010, that selectively depletes Tregs without the IL-2 trade-off. In mouse models, this led to stronger immune activation and tumor stability. The findings suggest promising applications in combination with existing therapies to tackle treatment resistance and improve cancer outcomes.

Delve into the fascinating world of bifidobacterium and its potential to enhance cancer treatment. Discover how specific strains can boost the effectiveness of chemotherapy and immunotherapy. Learn about their role in regulating immune functions and reducing inflammation, which might lead to better outcomes for cancer patients. The discussion also covers the importance of dietary fiber in supporting bifidobacterium growth. With calls for more clinical trials, the future of personalized cancer treatment looks promising!

Three cancer trial participants share their transformative journeys, illuminating the importance of patient-centered approaches in clinical research. They discuss the shift towards offering early-phase trials alongside biomarker therapies and spotlight the benefits, like access to novel treatments and emotional support. However, they also highlight barriers like restrictive eligibility and financial challenges that limit participation. Encouraging broader access, improved communication, and enhanced patient advocacy are key recommendations to foster a more inclusive trial environment.

New research reveals that lower levels of LRIG1 protein are linked to aggressive gliomas, significantly impacting tumor severity. The study examines three LRIG proteins and their roles in cell growth, highlighting the contrast between low and high-grade tumors. While primary glioblastomas display the lowest LRIG1 levels, secondary tumors maintain higher expressions. Additionally, the mysterious patterns of LRIG2 suggest post-transcriptional regulation, raising questions about its function. These findings could pave the way for new biomarkers and therapies in brain tumor treatment.

Discover how researchers are enhancing the antiviral drug cidofovir using eco-friendly cerium oxide nanoparticles, known as CDV-CeO2 NPs. This innovative method utilizes quince peel extract for sustainable synthesis, eliminating toxic chemicals. Laboratory results show these nanoparticles obliterate over 97% of breast cancer cells, showcasing their remarkable efficacy. Unpacking their dual action, the team discusses the binding mechanisms with DNA and RNA, offering exciting prospects for safer cancer and antiviral therapies.

Prostate cancer remains a formidable challenge, especially in low-oxygen environments. Researchers reveal how hypoxia allows cancer cells to resist ferroptosis, a potent treatment method aimed at destroying them. In these oxygen-poor areas, lipid metabolism shifts towards stable fats, making cells less susceptible to therapies. The study suggests innovative strategies, combining ferroptosis drugs with lipid storage inhibitors to enhance treatment efficacy. Insights gained could also apply to other solid tumors facing similar hypoxic challenges.

Explore the complexities of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer often confused with leukemia. Discover insights from a genetic study that identifies common mutations linked to survival. Learn about CCDC50, a potential diagnostic marker that could improve diagnosis and treatment response monitoring. The discussion highlights the importance of understanding BPDCN's genetic profile while addressing the need for larger studies to confirm these findings.

Exciting new research uncovers the widespread presence of folate receptor beta in pediatric solid tumors, paving the way for innovative surgical techniques. This discovery could significantly enhance fluorescence-guided surgery, using the targeted imaging agent pafolacianine. Unlike existing dyes, which lack tumor specificity, pafolacianine may offer safer and more effective surgical options. The podcast also highlights a forthcoming clinical trial aimed at using this technology in children with metastatic lung tumors, promising a hopeful future for pediatric cancer surgery.